GLIOMATHERAPY

R&D Projects

Immunotherapy with a monoclonal antibody against high-grade brain tumors.

NEW MARKERS OTHER PROJECTS

The overall objective of this project is to determine the therapeutic potential of the monoclonal antibody Nilo1 for the treatment of high-grade human brain tumours, either as a single treatment or in combination with other genotoxic drugs.

The Nilo1 monoclonal antibody has been generated against mouse neurosphere cell surface antigens and recognises mouse neural stem cells (type-B astrocytes) under both physiological and pathological conditions. Recent experiments have also shown that Nilo1 recognises a subpopulation of cells in malignant gliomas of the adult human brain, and is able to inhibit neurosphere proliferation in vitro.

2

leading research centres endorse the project

The research tests the potential of the Nilo1 antibody for the treatment of high-grade human brain tumours.

In order to determine its therapeutic potential in high-grade human brain tumours, its use in the diagnosis of human brain tumours will be validated, its inhibitory potential in human brain tumour spheres will be tested and its therapeutic effect in xenotransplanted` will be assessed.

To achieve the objectives

RTC-2015-3846-1 2015-2018

In order to successfully achieve the project’s aim, a consortium has been formed with the Biological Research Centre of the Spanish National Research Council (CIB-CSIC) and the Madrid Institute for Advanced Studies in Nanoscience Foundation (IMDEA nanociencia).

The project is co-funded by the Ministry of Economy and Competitiveness, within the call Challenges-Collaboration of the State Programme for Research, Development and Innovation Oriented to the Challenges of Society, in the framework of the State Plan for Scientific and Technical Research and Innovation 2013-2016, and by the European Regional Development Fund (ERDF).